المؤلفون: L. V. Egshatyan

المصدر: Медицинский совет, Vol 0, Iss 10, Pp 132-139 (2022)

مصطلحات موضوعية: hemodialysis, paricalcitol, vitamin d receptor activators, secondary hyperparathyroidism, vitamin d, parathyroid hormone, klotho, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/6940Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/4110958323c246f7b5aa258b7ec1bb47Test

المؤلفون: L. I. Ibragimova, E. A. Kolpakova, A. V. Dzagakhova, L. V. Egshatyan, E. V. Pokrovskaya, O. S. Derevyanko, T. V. Nikonova

المصدر: Сахарный диабет, Vol 24, Iss 1, Pp 62-69 (2021)

مصطلحات موضوعية: microbiota, type 1 diabetes mellitus, gene sequencing, Nutritional diseases. Deficiency diseases, RC620-627

وصف الملف: electronic resource

العلاقة: https://www.dia-endojournals.ru/jour/article/view/10326Test; https://doaj.org/toc/2072-0351Test; https://doaj.org/toc/2072-0378Test

الوصول الحر: https://doaj.org/article/2bd2887710424625b52597886d6e70feTest

المؤلفون: L. V. Egshatyan, L. Ya. Rozhinskaya, N. S. Kuznetsov, M. Sh. Shamkhalova

المصدر: Рациональная фармакотерапия в кардиологии, Vol 9, Iss 2, Pp 152-157 (2015)

مصطلحات موضوعية: вторичный гиперпаратиреоз, паратиреоидэктомия, цинакалцет, почечная анемия, дислипидемия, артериальная гипертензия, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: http://www.rpcardio.ru/jour/article/view/275Test; https://doaj.org/toc/1819-6446Test; https://doaj.org/toc/2225-3653Test

الوصول الحر: https://doaj.org/article/e00d86bc59fd4fb0a305dd039576982eTest

المؤلفون: L. V. Egshatyan, O. N. Tkacheva, S. A. Boytsov

المصدر: Кардиоваскулярная терапия и профилактика, Vol 13, Iss 6, Pp 56-61 (2014)

مصطلحات موضوعية: кишечная микробиота, атеросклероз, холин, l-карнитин, триметиламин-n-оксид, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://cardiovascular.elpub.ru/jour/article/view/83Test; https://doaj.org/toc/1728-8800Test; https://doaj.org/toc/2619-0125Test

الوصول الحر: https://doaj.org/article/f7db26c51763496eb03df04be5b33d6eTest

المؤلفون: L. Ya. Rozhinskaya, L. V. Egshatyan

المصدر: Остеопороз и остеопатии, Vol 13, Iss 2, Pp 18-22 (2010)

مصطلحات موضوعية: Osteopathy, RZ301-397.5

وصف الملف: electronic resource

العلاقة: https://endojournals.ru/index.php/osteo/article/view/4143Test; https://doaj.org/toc/2072-2680Test; https://doaj.org/toc/2311-0716Test

الوصول الحر: https://doaj.org/article/9d2eb72fdb8642caba8f310695a883e0Test

المؤلفون: L. V. Egshatyan, Л. В. Егшатян

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2023); 116-121 ; Медицинский Совет; № 13 (2023); 116-121 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: коррекция гипергликемии, chronic hyperglycemia, incretin system, combination therapy, correction for hyperglycemia, хроническая гипергликемия, инкретиновая система, комбинированная терапия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7719/6854Test; Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E, Cull C.A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. https://doi.org/10.1136/bmj.321.7258.405Test.; Kawanami D., Matoba K., Sango K., Utsunomiya K. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence. Int J Mol Sci. 2016;17(8):1223. https://doi.org/10.3390/ijms17081223Test.; Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu C. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(7):1670. https://doi.org/10.2337/dci19-0066Test.; Bayliss W., Starling E. The mechanism of pancreatic secretion. J Physiol. 1902;28(5):325–353. https://doi.org/10.1113/jphysiol.1902.sp000920Test.; Moore B. On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane. Biochem J. 1906;1(1):28–38. https://doi.org/10.1042/bj0010028Test.; Hartmann B., Johnsen A.H., Orskov C., Adelhorst K., Thim L., Holst J.J. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 2000;21(1):73–80. https://doi.org/10.1016/s0196-9781Test(99)00176-x.; Oduori O.S., Murao N., Shimomura K., Takahashi H., Zhang Q., Dou H. et al. Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes. J Clin Invest. 2020;130(12):6639–6655. https://doi.org/10.1172/JCI140046Test.; Müller T.D., Finan B., Bloom S.R., D'Alessio D., Drucker D.J., Flatt P.R. et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. https://doi.org/10.1016/j.molmet.2019.09.010Test.; Artasensi A., Pedretti A., Vistoli G., Fumagalli L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules. 2020;25(8):1987. https://doi.org/10.3390/molecules25081987Test.; Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52. https://doi.org/10.1007/BF02427280Test.; Eldor R., Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud. 2009;6(1):6–12. https://doi.org/10.1900/RDS.2009.6.6Test.; Davidson J.A. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med. 2009;76(5):S28–S38. https://doi.org/10.3949/ccjm.76.s5.05Test.; Dicker D. DPP-4 Inhibitors. Impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34(2):276–278. https://doi.org/10.2337/dc11-s229Test.; Jeon J.Y., Ko S.H., Kwon H.S., Kim N.H., Kim J.H., Kim C.S. et al. Prevalence of diabetesand prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J. 2013;37(5):349–357. https://doi.org/10.4093/dmj.2013.37.5.349Test.; Plosker G.L. Sitagliptin: A review of its use in patientswith type 2 diabetes mellitus. Drugs. 2014;74(2):223–242. https://doi.org/10.1007/s40265013-0169-1Test.; Onge E.L., Miller S., Clements E. Sitagliptin/metformin (Janumet) as combination therapy in the treatment of type-2 diabetes mellitus. PT. 2012;37(12): 699–708. Available at: https://pubmed.ncbi.nlm.nih.gov/23319848Test/.; Herman G.A., Stevens C., Van Dyck K., Bergman А., Yi B., Smet М.D. et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688. https://doi.org/10.1016/j.clpt.2005.09.002Test.; Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H.; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–2571. https://doi.org/10.1007/s00125-006-0416-zTest.; Mannucci E., Pala L., Ciani S., Bardini G., Pezzatini A., Sposato I. et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48(6):1168–1172. https://doi.org/10.1007/s00125-005-1749-8Test.; Katsuno T., Ikeda H., Namba M. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2016;7(2):309–320. https://doi.org/10.1007/s13300-016-0170-2Test.; Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69–73. https://doi.org/10.1507/endocrj.k10e-382Test.; Vincent S.H., Reed J.R., Bergman A.J., Elmore C.S., Zhu B., Xu S. et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos. 2007;35(4):533–538. https://doi.org/10.1124/dmd.106.013136Test.; Engel S.S., Golm G.T., Shapiro D., Davies M.J., Kaufman K.D., Goldstein B.J. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3. https://doi.org/10.1186/1475-2840-12-3Test.; Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–242. https://doi.org/10.1056/NEJMoa1501352Test.; Bailey C.J., Campbell J.W., Chan J.C.N., Davidson J.A., Howlett H.C.S., Ritz P. Metformin. The Gold Standard: а Scientific Handbook. 2007. P. 37. Available at: https://research.aston.ac.uk/en/publications/metformin-the-gold-standard-a-scientific-handbookTest.; LaMoia T.E., Shulman G.I. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021;42(1):77–96. https://doi.org/10.1210/endrev/bnaa023Test.; Migoya E.M., Bergeron R., Miller J.L., Snyder R.N., Tanen M., Hilliard D. et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010;88(6):801–808. https://doi.org/10.1038/clpt.2010.184Test.; Maida A., Lamont B.J., Cao X., Drucker D.J. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia. 2011;54(2):339–349. https://doi.org/10.1007/s00125-010-1937-zTest.; Liu X., Wang L., Xing Y., Engel S.S., Zeng L., Yao B. et al. Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study. J Diabetes Investig. 2020;11(6):1532–1541. https://doi.org/10.1111/jdi.13277Test.; Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. https://doi.org/10.2337/db09-9028Test.; Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., Williams-Herman D.E. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987. https://doi.org/10.2337/dc07-0627Test.; Reasner C., Olansky L., Seck T.L., Williams-Herman D.E., Chen M., Terranella L. et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(7):644–652. https://doi.org/10.1111/j.1463-1326.2011.01390.xTest.; Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P. et al., Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562–576. https://doi.org/10.1111/j.1742-1241.2010.02353.xTest.; Standards of Medical Care in Diabetes-2016. Obesity Management for the Treatment of Type 2 Diabetes. Diabetes Care. 2016;39(S1):S47–S51. https://doi.org/10.2337/dc16-S009Test.; Janani L., Bamehr H., Tanha K., Mirzabeigi P., Montazeri H., Tarighi P. Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Drug Res (Stuttg). 2021;71(9):477–488. https://doi.org/10.1055/a-1555-2797Test.; Janghorbani M., Van Dam R.M., Willett W.C., Hu F.B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505. https://doi.org/10.1093/aje/kwm106Test.; Zhen D., Chen Y., Tang X. Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications. 2010;24(5):334–344. https://doi.org/10.1016/j.jdiacomp.2009.05.002Test.; Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsbøll T., Hartmann B., Henriksen E.E. et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res. 2003;18(12):2180–2189. https://doi.org/10.1359/jbmr.2003.18.12.2180Test.; Choi H.J., Park C., Lee Y.K., Ha Y.C., Jang S., Shin C.S. Risk of fractures and diabetes medications: a nationwide cohort study. Osteoporos Int. 2016;27(9):2709–2715. https://doi.org/10.1007/s00198-016-3595-6Test.; https://www.med-sovet.pro/jour/article/view/7719Test

الإتاحة: https://doi.org/10.21518/ms2023-168Test
https://doi.org/10.1136/bmj.321.7258.405Test
https://doi.org/10.3390/ijms17081223Test
https://doi.org/10.2337/dci19-0066Test
https://doi.org/10.1113/jphysiol.1902.sp000920Test
https://doi.org/10.1042/bj0010028Test
https://doi.org/10.1016/s0196-9781Test(99)00176-x
https://doi.org/10.1172/JCI140046Test
https://doi.org/10.1016/j.molmet.2019.09.010Test
https://doi.org/10.3390/molecules25081987Test

المؤلفون: A. M. Mkrtumyan, L. V. Egshatyan, А. М. Мкртумян, Л. В. Егшатян

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2023); 264-273 ; Медицинский Совет; № 6 (2023); 264-273 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: клиническая программа SUSTAIN, semaglutide, glucagon-like peptide-1 receptor agonists, cardiovascular complications, SUSTAIN clinical program, семаглутид, агонисты рецепторов глюкагоноподобного пептида 1, сердечно-сосудистые осложнения

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7275/6501Test; Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17Test.; Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759Test.; Diabetes Control and Complications Trial Research Group, Nathan D.M., Genuth S., Lachin J., Cleary P., Crofford O., Davis M. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. https://doi.org/10.1056/NEJM199309303291401Test.; Della Corte V., Tuttolomondo A., Pecoraro R., Di Raimondo D., Vassallo V., Pinto A. Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr Pharm Des. 2016;22(30):4658–4668. https://doi.org/10.2174/1381612822666160510124801Test.; Giblett J.P., Axell R.G., White P.A., Clarke S.J., McCormick L., Read P.A. et al. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovasc Diabetol. 2016;15:99. https://doi.org/10.1186/s12933-016-0416-3Test.; Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209-15. https://doi.org/10.1152/ajpendo.00237.2004Test.; Aldiss P., Davies G., Woods R., Budge H., Sacks H.S., Symonds M.E. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265–274. https://doi.org/10.1016/j.ijcard.2016.11.074Test.; Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Pénicaud L. et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes. 2008;57(10):2577–2587. https://doi.org/10.2337/db08-0121Test.; Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53:2181–2189. https://doi.org/10.2337/diabetes.53.9.2181Test.; White J.R. A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2014;27(2):82–86. https://doi.org/10.2337/diaspect.27.2.82Test.; Gram D.X., Knudsen S.M., Nielsen F.S., Thygesen P., Reedtz-Runge S., Kruse T. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726Test.; Sorli C., Harashima S.I., Tsoukas G.M., Unger J., Karsbøl J.D., Hansen T., Bain S.C. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. https://doi.org/10.1016/S2213-8587Test(17)30013-X.; Ahrén B., Masmiquel L., Kumar H., Sargin M., Karsbøl J.D., Jacobsen S.H., Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354. https://doi.org/10.1016/S2213-8587Test(17)30092-X.; Ahmann A.J., Capehorn M., Charpentier G., Dotta F., Henkel E., Lingvay I. et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018;41(2):258–266. https://doi.org/10.2337/dc17-0417Test.; Aroda V.R., Bain S.C., Cariou B., Piletič M., Rose L., Axelsen M. et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as addon to metformin (with or without sulfonylureas) in insulinnaive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. https://doi.org/10.1016/S2213-8587Test(17)30085-2.; Rodbard H.W., Lingvay I., Reed J., de la Rosa R., Rose L., Sugimoto D. et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301. https://doi.org/10.1210/jc.2018-00070Test.; Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A. et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141Test.; Pratley R.E., Aroda V.R., Lingvay I., Lüdemann J., Andreassen C., Navarria A., Viljoen A.; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. https://doi.org/10.1016/S2213-8587Test(18)30024-X.; Lingvay I., Catarig A.M., Frias J.P., Kumar H., Lausvig N.L., le Roux C.W. et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–844. https://doi.org/10.1016/S2213-8587Test(19)30311-0.; Zinman B., Bhosekar V., Busch R., Holst I., Ludvik B., Thielke D. et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9) : a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367. https://doi.org/10.1016/S2213-8587Test(19)30066-X.; Capehorn M.S., Catarig A.M., Furberg J.K., Janez A., Price H.C., Tadayon S. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–109. https://doi.org/10.1016/j.diabet.2019.101117Test.; Kaku K., Yamada Y., Watada H., Abiko A., Nishida T., Zacho J., Kiyosue A. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes Obes Metab. 2018;20(5):1202–1212. https://doi.org/10.1111/dom.13218Test.; Chun J.H., Butts A. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. JAAPA. 2020;33(8):3–18. https://doi.org/10.1097/01Test. JAA.0000669456.13763.bd.; Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. https://doi.org/10.1016/j.jacc.2019.03.010Test.; Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M. et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868Test.; Pantalone K.M., Misra-Hebert A.D., Hobbs T.M., Ji X., Kong S.X., Milinovich A. et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54. https://doi.org/10.1186/s12933-018-0699-7Test.; Шестакова М.В., Шамхалова М.Ш., Галстян Г.Р., Руяткина Л.А., Суплотова Л.А. Пероральный семаглутид – новая инновационная опция в терапии сахарного диабета 2 типа. Сахарный диабет. 2021;24(3):273–281. https://doi.org/10.14341/DM12790Test.; Rakipovski G., Rolin B., Nøhr J., Klewe I., Frederiksen K.S., Augustin R. et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844–857. https://doi.org/10.1016/j.jacbts.2018.09.004Test.; Pratley R.E., Crowley M.J., Gislum M., Hertz C.L., Jensen T.B., Khunti K. et al. Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Ther. 2021;12(4):1099–1116. https://doi.org/10.1007/s13300-020-00994-9Test.; Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486Test.; Introduction: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl. 1):1–2. https://doi.org/10.2337/dc19-SINT01Test.; American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):98–110. https://doi.org/10.2337/dc20-S009Test.; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 10-й выпуск. Сахарный диабет. 2021;24(Suppl. 1):1–148. https://doi.org/10.14341/DM12802Test.; https://www.med-sovet.pro/jour/article/view/7275Test

الإتاحة: https://doi.org/10.21518/ms2022-010Test
https://doi.org/10.14341/DM2004116-17Test
https://doi.org/10.14341/DM12759Test
https://doi.org/10.1056/NEJM199309303291401Test
https://doi.org/10.2174/1381612822666160510124801Test
https://doi.org/10.1186/s12933-016-0416-3Test
https://doi.org/10.1152/ajpendo.00237.2004Test
https://doi.org/10.1016/j.ijcard.2016.11.074Test
https://doi.org/10.2337/db08-0121Test
https://doi.org/10.2337/diabetes.53.9.2181Test

المؤلفون: Tatiana Vasil'evna Nikonova, Liudmila I. Ibragimova, E. V. Pokrovskaya, Olga Sergeevna Derevyanko, A. V. Dzagakhova, E. A. Kolpakova, L. V. Egshatyan

المصدر: Сахарный диабет, Vol 24, Iss 1, Pp 62-69 (2021)

مصطلحات موضوعية: 0301 basic medicine, Type 1 diabetes, RC620-627, biology, endocrine system diseases, gene sequencing, business.industry, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Gut flora, biology.organism_classification, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Endocrinology, Immunology, Internal Medicine, microbiota, Medicine, business, Nutritional diseases. Deficiency diseases, type 1 diabetes mellitus

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c04503a5e27d489d11b776336d7d97Test
https://www.dia-endojournals.ru/jour/article/view/10326Test

المؤلفون: L. V. Egshatyan

المصدر: Nephrology (Saint-Petersburg). 24:100-106

مصطلحات موضوعية: Paricalcitol, medicine.medical_specialty, Cinacalcet, business.industry, Calcimimetic, Parathyroid hormone, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, medicine.disease, Gastroenterology, vitamin D deficiency, 03 medical and health sciences, Hyperphosphatemia, 0302 clinical medicine, medicine.anatomical_structure, Nephrology, Internal medicine, medicine, Secondary hyperparathyroidism, Parathyroid gland, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::bd2a2044925a1657859b5398ff9d4a29Test
https://doi.org/10.36485/1561-6274-2020-24-6-100-106Test

المؤلفون: D A Kashtanova, O N Tkacheva, L V Egshatyan, E V Plokhova, A S Popenko, A V Tyakht, D G Alexeev, Yu V Kotovskaya, S А Boytsov

المصدر: Клиническая практика, Vol 7, Iss 3, Pp 62-72 (2016)

مصطلحات موضوعية: gut microbiota, 16s rrna sequencing, pulse wave velocity, atherosclerosis, Medicine

العلاقة: https://journals.eco-vector.com/clinpractice/article/viewFile/8110/6532Test; https://doaj.org/toc/2220-3095Test; https://doaj.org/toc/2618-8627Test; https://doaj.org/article/657031249b184d5f879b0b71a8252fc2Test

الإتاحة: https://doi.org/10.17816/clinpract7362-72Test
https://doaj.org/article/657031249b184d5f879b0b71a8252fc2Test